IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.447
AS - Asia 3.551
EU - Europa 2.268
SA - Sud America 827
AF - Africa 87
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 21
Totale 12.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.163
SG - Singapore 1.607
IT - Italia 1.004
CN - Cina 775
BR - Brasile 647
IN - India 533
SE - Svezia 317
GB - Regno Unito 309
VN - Vietnam 254
DE - Germania 253
CA - Canada 224
FI - Finlandia 90
AR - Argentina 65
HK - Hong Kong 64
ID - Indonesia 55
NL - Olanda 49
BD - Bangladesh 39
RU - Federazione Russa 37
MX - Messico 36
ZA - Sudafrica 33
EC - Ecuador 30
JP - Giappone 30
PK - Pakistan 30
ES - Italia 29
UA - Ucraina 29
FR - Francia 27
JO - Giordania 25
RO - Romania 24
CO - Colombia 22
EU - Europa 22
IQ - Iraq 22
PY - Paraguay 20
PL - Polonia 19
TR - Turchia 18
EG - Egitto 16
IR - Iran 16
SA - Arabia Saudita 16
AU - Australia 15
AT - Austria 14
CZ - Repubblica Ceca 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
CL - Cile 12
LT - Lituania 11
PE - Perù 11
PT - Portogallo 9
EE - Estonia 8
NG - Nigeria 8
TN - Tunisia 8
MA - Marocco 7
MY - Malesia 7
ET - Etiopia 6
IE - Irlanda 6
LB - Libano 6
UY - Uruguay 6
BG - Bulgaria 5
GT - Guatemala 5
KR - Corea 5
CU - Cuba 4
CY - Cipro 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TW - Taiwan 4
AL - Albania 3
DO - Repubblica Dominicana 3
HN - Honduras 3
IL - Israele 3
KE - Kenya 3
LK - Sri Lanka 3
NP - Nepal 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
CH - Svizzera 2
DZ - Algeria 2
HR - Croazia 2
HU - Ungheria 2
KI - Kiribati 2
PA - Panama 2
PS - Palestinian Territory 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
GE - Georgia 1
GM - Gambi 1
GR - Grecia 1
JM - Giamaica 1
KW - Kuwait 1
KZ - Kazakistan 1
NI - Nicaragua 1
OM - Oman 1
PR - Porto Rico 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 12.222
Salva come PNG Salva come JPEG
Città #
Chandler 807
Singapore 659
Santa Clara 412
Hefei 390
Bengaluru 388
Dallas 368
Milan 352
Lawrence 343
Princeton 343
Chicago 243
London 214
Munich 198
Wilmington 185
Ashburn 176
Ottawa 160
Des Moines 115
Catanzaro 105
Ho Chi Minh City 100
Turku 66
Boardman 60
São Paulo 60
Beijing 59
Los Angeles 59
Hong Kong 54
Hanoi 49
Shanghai 43
New York 42
Rome 36
Pune 35
Norwalk 34
Guangzhou 30
Brooklyn 28
Council Bluffs 28
Rio de Janeiro 28
San Francisco 28
Redmond 27
Helsinki 24
Naples 24
The Dalles 24
Montreal 22
Redwood City 21
Tokyo 21
Warsaw 20
Manchester 18
Amman 17
Chennai 17
Columbus 16
Parma 16
San Nicola Manfredi 16
Shenzhen 16
Stockholm 16
Atlanta 14
Johannesburg 13
Seattle 13
Thái Bình 13
Toronto 13
Augusta 12
Carbonia 12
Cosenza 12
Horia 12
Palermo 12
Phoenix 12
Reggio Calabria 12
Spezzano della Sila 12
Boston 11
Dhaka 11
Hanover 11
Mountain View 11
Olomouc 11
Porto Alegre 11
Cape Town 10
Curitiba 10
Delhi 10
Denver 10
Haiphong 10
Mexico City 10
West Jordan 10
Amsterdam 9
Ankara 9
Belo Horizonte 9
Da Nang 9
Jiaxing 9
Salvador 9
Afragola 8
Asunción 8
Baghdad 8
Ercolano 8
Guarulhos 8
Irbid 8
Jakarta 8
Las Vegas 8
Madrid 8
Manaus 8
Santo Stefano di Rogliano 8
Sorocaba 8
Washington 8
Buenos Aires 7
Charlotte 7
Frankfurt am Main 7
Guayaquil 7
Totale 7.096
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 398
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 110
miR-22 suppresses DNA ligase III addiction in multiple myeloma 91
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 90
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 79
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 75
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 67
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 65
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 65
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 64
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 64
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 64
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 64
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 63
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 59
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 59
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 58
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 55
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 55
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 54
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 54
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 54
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 53
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 52
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 52
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 52
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 52
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 52
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 52
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 52
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 51
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 51
Mir-34: a new weapon against cancer? 50
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 50
miR-221/222 inhibitors for the treatment of multiple myeloma 50
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 49
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 49
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 49
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 48
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 48
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 47
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 47
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 47
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 46
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 46
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 46
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 45
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 45
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 45
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 44
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 44
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 44
Mir-221/222 are promising targets for innovative anticancer therapy 44
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 44
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 44
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 44
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 44
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 44
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 43
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 43
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 43
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 43
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 43
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 43
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 43
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 42
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 42
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 42
Fetal ontogeny and tumor expression of the early thymic antigen UN1 42
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 42
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 42
Familial papillary thyroid microcarcinoma: a new clinical entity 42
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 42
Anti-myeloma activity of miR-125 mimics 42
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 41
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma 41
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 41
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 41
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 40
A PH-DEPENDENT DIFFERENTIAL CYTO-TOXICITY OF OUABAIN FOR HUMAN-CELLS TRANSFORMED BY CERTAIN ONCOGENES 40
miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. 40
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 40
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 40
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 40
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo 40
Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta) 40
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 40
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 40
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 40
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 40
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 39
REVERSAL OF ADRIAMYCIN RESISTANCE BY RECOMBINANT ALPHA-INTERFERON IN MULTIDRUG-RESISTANT HUMAN COLON-CARCINOMA LOVO-DOXORUBICIN CELLS 39
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 39
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 39
Analysis of miRNA, mRNA, and TF interactions through network-based methods 39
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 39
Inibitore LNA-miR-221 per il trattamento dei tumori 39
The eukariotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells 39
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 39
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 39
Totale 5.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 155.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 155.745
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021310 0 0 0 18 45 31 33 16 48 69 44 6
2021/2022952 17 6 12 278 50 19 31 197 95 91 144 12
2022/20232.556 706 75 83 206 274 227 13 161 387 160 214 50
2023/20241.353 310 134 115 93 94 320 40 53 15 46 61 72
2024/20254.071 551 241 183 127 225 512 108 153 477 247 415 832
2025/20262.924 406 880 791 847 0 0 0 0 0 0 0 0
Totale 12.509